LeadIQ logo
Learn more at LeadIQ.com

Insights

Strategic Focus Privately held clinical stage biotech leveraging the UNITE nucleic acid immunotherapy platform to develop broad immune responses across cancer, allergy, and infectious diseases, indicating potential cross-disease collaboration and licensing opportunities.

Vaccine Platform UNITE based vaccines and cancer cell vaccine programs such as ITI-1000 suggest partnership potential with immunotherapy developers, biotech firms pursuing dendritic cell vaccine approaches, and CMV-related oncology initiatives.

Clinical Stage Advantage Small to mid-size team (11-50 employees) with ongoing clinical development implies opportunities for CRO/CMO partnerships, clinical trial support, and strategic alliances to accelerate program milestones.

Financial Position Revenue in the low tens of millions with substantial funding (~$85M) provides runway for collaboration on co-development, milestone-driven deals, and joint ventures with larger biotech manufacturers or vaccine developers.

Market Positioning Consistent messaging around broad immune responses and UNITE platform positions ITI to engage with companies pursuing novel immunotherapies, personalized vaccines, or antibody development collaborations.

Similar companies to Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. Tech Stack

Immunomic Therapeutics, Inc. uses 8 technology products and services including QuickBooks, iCIMS, WordPress, and more. Explore Immunomic Therapeutics, Inc.'s tech stack below.

Media & News

Immunomic Therapeutics, Inc.'s Email Address Formats

Immunomic Therapeutics, Inc. uses at least 4 email formats:
Immunomic Therapeutics, Inc. Email FormatsExamplePercentage
FLast@immunomix.comJDoe@immunomix.com
89%
First.Last@immunomix.comJohn.Doe@immunomix.com
8%
FirstLa@immunomix.comJohnDo@immunomix.com
2%
First_Last@immunomix.comJohn_Doe@immunomix.com
1%

Frequently Asked Questions

What is Immunomic Therapeutics, Inc.'s phone number?

Minus sign iconPlus sign icon You can contact Immunomic Therapeutics, Inc.'s main corporate office by phone at
+1-866-515-****
. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Immunomic Therapeutics, Inc.'s official website and social media links?

Minus sign iconPlus sign iconImmunomic Therapeutics, Inc.'s official website is immunomix.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Immunomic Therapeutics, Inc. generate?

Minus sign iconPlus sign icon As of October 2026, Immunomic Therapeutics, Inc.'s annual revenue is estimated to be $10M - $25M.

What is Immunomic Therapeutics, Inc.'s SIC code and NAICS code?

Minus sign iconPlus sign iconImmunomic Therapeutics, Inc.'s SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Immunomic Therapeutics, Inc. have currently?

Minus sign iconPlus sign iconAs of October 2026, Immunomic Therapeutics, Inc. has approximately 20 employees across 1 continents, including North America. Key team members include Vice President Of Quality Assurance: C. S., Sr. Vice President Of Regulatory Affairs: F. H. and Director, Rna Therapeutic Development And Cmc: P. K. Explore Immunomic Therapeutics, Inc.'s employee directory with LeadIQ.

What industry does Immunomic Therapeutics, Inc. belong to?

Minus sign iconPlus sign iconImmunomic Therapeutics, Inc. operates in the Biotechnology Research industry.

What technology does Immunomic Therapeutics, Inc. use?

Minus sign iconPlus sign iconImmunomic Therapeutics, Inc.'s tech stack includes QuickBooks, iCIMS, WordPress, SAP, Shopify, Microsoft 365, Google Fonts API and Piwik PRO Core.

What is Immunomic Therapeutics, Inc.'s email format?

Minus sign iconPlus sign iconImmunomic Therapeutics, Inc.'s email format typically follows the pattern of FLast@immunomix.com. Find more Immunomic Therapeutics, Inc. email formats with LeadIQ.

How much funding has Immunomic Therapeutics, Inc. raised to date?

Minus sign iconPlus sign icon As of October 2026, Immunomic Therapeutics, Inc. has raised $85M in funding. The last funding round occurred on Jun 02, 2025 for $6.5M.

When was Immunomic Therapeutics, Inc. founded?

Minus sign iconPlus sign iconImmunomic Therapeutics, Inc. was founded in 2005.
Immunomic Therapeutics, Inc. logo

Immunomic Therapeutics, Inc.

Biotechnology ResearchMaryland, United States11-50 Employees

Immunomic Therapeutics, Inc. is a privately held, clinical-stage biotechnology company based in Rockville, Maryland. It focuses on immunotherapy and vaccines, with the aim of eliciting broad immune responses against cancer, allergies, and infectious diseases through its UNITE platform, which enables intracellular expression of vaccine components. ITI is developing ITI-1000, a cancer vaccine that uses autologous dendritic cells loaded with CMV pp65 mRNA. The company also pursues collaborations to develop antibody candidates and broaden its therapeutic scope. In 2024, ITI described work on vaccines designed to generate broad immune responses through its UNITE platform, indicating ongoing activity and partnerships.

Section iconCompany Overview

Phone number
+1-866-515-****
Website
immunomix.com
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2005
Employees
11-50

Section iconMedia & News

Section iconFunding & Financials

  • $85M

    Immunomic Therapeutics, Inc. has raised a total of $85M of funding over 11 rounds. Their latest funding round was raised on Jun 02, 2025 in the amount of $6.5M as a Venture Round.

  • $10M - $25M

    Immunomic Therapeutics, Inc.'s revenue is estimated to be in the range of $10M - $25M

Company Leadership

  • Vice President Of Quality Assurance at Immunomic Therapeutics, Inc.
    C. S.
    Vice President Of Quality Assurance
    Mobile Phone
  • Sr. Vice President Of Regulatory Affairs at Immunomic Therapeutics, Inc.
    F. H.
    Sr. Vice President Of Regulatory Affairs
    Mobile Phone
  • Director, Rna Therapeutic Development And Cmc at Immunomic Therapeutics, Inc.
    P. K.
    Director, Rna Therapeutic Development And Cmc
    Mobile Phone
  • Director, Translational Research at Immunomic Therapeutics, Inc.
    C. B. R.
    Director, Translational Research
    Mobile Phone
  • Project Manager at Immunomic Therapeutics, Inc.
    E. R. B.
    Project Manager
    Mobile Phone

Employee Directory

  • Biopharma at Immunomic Therapeutics, Inc.
    J. M.
    Biopharma
    Mobile Phone
  • Registered Nurse at Immunomic Therapeutics, Inc.
    M. M.
    Registered Nurse
    Mobile Phone
  • Strategic Business Development Analyst at Immunomic Therapeutics, Inc.
    T. M.
    Strategic Business Development Analyst
    Mobile Phone
  • Process Development Associate Level Two at Immunomic Therapeutics, Inc.
    J. R.
    Process Development Associate Level Two
    Mobile Phone

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.